Enterprise Value
12.58M
Cash
1.421M
Avg Qtr Burn
-6.224M
Short % of Float
2.20%
Insider Ownership
28.19%
Institutional Own.
39.15%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis | Approved Quarterly sales | |
XEPI (ozenoxacin) Details Impetigo | Approved Quarterly sales | |
Ameluz (aminolevulinic acid hydrochloride) Details BCC (basal cell carcinoma), AK (actinic keratosis) | Approved Quarterly sales | |
Ameluz® - PDT (3 tubes) Details Actinic keratosis | PDUFA Approval decision | |
Ameluz® Details Actinic keratosis | Phase 3 Data readout | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis, Acne | Phase 2 Data readout |